Immune checkpoint inhibitors (ICIs) have changed cancer therapy, utilizing the immune system's natural ability to fight tumors. Immune checkpoint inhibitors block the inhibitory pathways in the immune system by enabling immune cells to be able to more effectively destroy cancer cells. The groundbreaking discoveries of immune checkpoint inhibitors have greatly impacted cancer treatment and have offered hope for the improvement of the survival of patients with different malignant tumors or cancers. To understand how ICIs revolutionize cancer treatment, it is important to explore their mechanisms and role in exploiting the immune system against tumors.
Immune checkpoint inhibitors are under the class of immunotherapy drugs that are created to prevent the immune checkpoint proteins from binding with their partner proteins. This obstruction prevents the "off" signal from the immune checkpoint proteins and partner proteins from being sent to the T-cells, allowing the immune system to attack the cancer cells. These therapies work by targeting immune checkpoints, which regulate the immune response.
Immune checkpoints are regulators that are essential to the immune system. Their main role is to maintain immune tolerance and to keep the immune system from attacking healthy cells. Immune checkpoints use proteins that are expressed on the surface of T-cells that interact with their partner proteins of other cells, such as tumor cells. When the surface T-cell proteins and the partner proteins bind, they send signals to deactivate the T-cells which prevents immune responses.
Tumor cells utilize these immune checkpoints by overexpressing ligands (ions or neutral molecules that bind to a central metal atom or ion) like PD-L1 that bind to receptors and deactivate T-cells which leads to immune evasion. This process forms the framework for targeting immune checkpoints in cancer therapy.
The main checkpoints include:
PD-1/PD-L1
A receptor on T-cells.
Its ligand PD-L1 is often overexpressed by tumor cells.
The interaction between PD-1 and PD-L1 subdues T-cell activity, which allows tumors to avoid immune responses.
CTLA-4
An inhibitory receptor in T-cells.
It competes with CD28 for binding to CD80 and CD86.
It downregulates T-cell activation which prevents an excessive immune response.
LAG-3
An immune checkpoint receptor that is expressed on activated T-cells, regulatory T-cells, and natural killer cells.
It negatively regulates T-cell activation and proliferation.
TIM-3
An inhibitory receptor that is expressed on T-cells and other immune cells.
It plays a role in decreasing immune responses, such as in cases of chronic inflammation and cancer.
Immune checkpoint inhibitors therefore block the interaction between checkpoint proteins and their ligands which restore T-cell activity. This method is effective after treatments such as chemotherapy, radiotherapy, and surgery. This is because it strengthens the immune system's ability to destroy residual tumor cells.
However, some patients present with resistance to immune checkpoint inhibitors because of tumor-specific mechanisms that suppress the immune responses. Tumor cells can produce high levels of checkpoint ligands and manipulate immune cells such as macrophages and dendritic cells to escape attack from T-cells. ICIs, such as those targeting PD-1/PD-L1 and CTLA-4, work to counter these events of evasion, which makes them a groundbreaking approach in immunotherapy.
The foundation of cancer prevention is the immune system's ability to recognize and eliminate tumors. However, tumors often avoid immune inspection by utilizing checkpoint pathways. Checkpoint pathways are what necessitated the development of immune checkpoint inhibitors. Two such pathways are PD-1/PD-L1 and CTLA-4 pathways.
PD-1/PD-L1 Pathway
ICIs targeting PD-1/PD-L1, such as pembrolizumab and nivolumab, block the interaction of PD-1 and PD-L1 (suppression of T-cell activity) and restores T-cell function.
This overcomes the immune suppression that is caused by tumors.
CTLA-4 Pathway
ICIs like ipilimumab block CTLA-4, preventing its inhibitory effects and activating the T-cells to target cancer cells.
These CTLA-4 inhibitors, enhance T-cell proliferation and differentiation which promotes anti-tumor immunity.
Tumors overexpress ligands such as PD-L1 in order to prevent T-cell activation and avoid immune destruction. This allows for tumor growth and metastasis.
Immune checkpoint inhibitors have transformed cancer treatment by using the immune system to target tumors. The success of ICIs in treating immunogenic cancers emphasizes their potential as a foundation of cancer therapy. However, regardless of their effectiveness, ICIs continue to face challenges such as resistance mechanisms and immune-related events. The continued investigation of immune checkpoint inhibitors could lead to shifts in oncology and offer hope for improved patient outcomes.
Sources